Rachel N. Steinmetz

TL;DR: Patients with relapsed/refractory B-ALL enrolled in a phase 1/2 clinical trial evaluating lymphodepletion chemotherapy followed by CD19 CAR T-cell therapy who might benefit from consolidation strategies such as allogeneic HCT are studied.

TL;DR: Analysis of clinical and treatment characteristics, serum biomarkers, and CAR T-cell manufacturing and pharmacokinetic data showed that a lower pre-lymphodepletion serum lactate dehydrogenase (LDH) level and a favorable cytokine profile, defined as serum day 0 monocyte chemoattractant protein-1 (MCP-1) and peak interleukin-7 (IL-7) concentrations above the median, were associated with better PFS.

TL;DR: CD19 CAR-T cell immunotherapy with concurrent ibrutinib for R/R CLL were well tolerated, with low CRS severity, and led to high rates of MRD-negative response by IGH sequencing.

TL;DR: CD19 CAR-T cell immunotherapy is highly effective in adults with clinically aggressive R/R follicular lymphoma with or without transformation, with durable remission in a high proportion of FL patients.

TL;DR: The identification of two modifiable pre-treatment factors independently associated with better outcomes after CART2 suggests strategies to improve in vivoCAR T-cell kinetics and responses after repeat CAR T- cell infusions, and has implications for the design of trials of novel CART-cell products after failure of prior CAR T -cell immunotherapies.